LLYLilly (Eli)
Is it growing?
Growing: revenue growing +50% year on year and earnings up +95% year on year.
Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +24% a year.
Trailing-twelve-month earnings per share against a year earlier. Growing faster than revenue, so margins or the share count are helping.
All from SEC EDGAR, as of Jun 30, 2026.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.
Is LLY growing?
Lilly (Eli) has grown revenue 39% a year over three years and 24% a year over five, with earnings per share compounding at 61%.
Revenue growth, 3-year annual rate · Drug Manufacturers - General median +6.3% · compounding fast · compounded from trailing twelve-month revenue
- Revenue growth, 5-year rate
- +24%
Revenue growth, 5-year rate · +39% over three · growth has picked up over the last three years
- Earnings per share, 3-year rate
- +61%
Earnings per share, 3-year rate · revenue +39% · earnings outgrew revenue: margins or the share count worked for shareholders
- Years of annual history on file
- 20
Years of annual history on file · FY2006 to FY2025, as filed
Details›
- Revenue FY2021
- $28.3B
- Revenue FY2022
- $28.5B
- Revenue FY2023
- $34.1B
- Revenue FY2024
- $45.0B
- Revenue FY2025
- $65.2B
Annual income statements as filed with the SEC.
Drug Manufacturers, General
The closest names by size in the same industry